Targeted upstream approaches, including gC1qR-directed therapeutics, may be preferred due to direct attenuation of molecular signaling pathways (Fandaros et al., 2022) that underlie the vascular changes and proinflammatory factors that drive edema generation in AIS. Here, C1QBP is linked to androgen insensitivity syndrome.